The first AI-designed drugs have ended with disappointment.
Over the last year-plus, the first handful of molecules created by artificial intelligence have failed trials or been deprioritized. The AI companies behind these drugs brought them into the clinic full of fanfare about a new age of drug discovery — and…
Click here to view original post
–Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development– SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc., (NASDAQ: CAPR), […]
DRAPER, Utah, Sept. 11, 2025 /PRNewswire/ — Nexus Spine is excited to share pilot study results of a comparative radiographic assessment of ACDF outcomes in a series of patients who were selected for common risk […]
Researchers engineered T cells to be more efficient and precise in their ability to kill prostate cancer cells. T cell receptors are modified to improve durability of the bond with cancer cells. The post Modifying […]
Copyright © 2026 Biotech Networks
